JMP Securities Reiterates Market Outperform Rating for Axon Enterprise (NASDAQ:AXON)

Axon Enterprise (NASDAQ:AXON)‘s stock had its “market outperform” rating reissued by stock analysts at JMP Securities in a report issued on Monday,Benzinga reports. They presently have a $825.00 price objective on the biotechnology company’s stock. JMP Securities’ price target would indicate a potential upside of 14.96% from the stock’s previous close.

Several other brokerages also recently issued reports on AXON. JPMorgan Chase & Co. boosted their price objective on Axon Enterprise from $730.00 to $850.00 and gave the stock an “overweight” rating in a research report on Thursday, July 17th. Raymond James Financial reiterated an “outperform” rating and set a $855.00 price target (up previously from $645.00) on shares of Axon Enterprise in a research report on Tuesday, August 5th. UBS Group reissued a “neutral” rating and issued a $840.00 price target (up previously from $820.00) on shares of Axon Enterprise in a research note on Tuesday, August 5th. Northland Securities set a $800.00 price objective on shares of Axon Enterprise in a research note on Tuesday, August 5th. Finally, Wolfe Research assumed coverage on shares of Axon Enterprise in a research report on Monday, July 7th. They issued an “outperform” rating for the company. Fourteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $841.64.

Axon Enterprise Stock Performance

Shares of AXON opened at $717.64 on Monday. The firm has a fifty day moving average of $757.83 and a 200-day moving average of $704.96. The company has a market cap of $56.34 billion, a price-to-earnings ratio of 177.20, a price-to-earnings-growth ratio of 27.80 and a beta of 1.40. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95. Axon Enterprise has a 1 year low of $395.37 and a 1 year high of $885.91.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Monday, August 4th. The biotechnology company reported $2.12 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.58. The firm had revenue of $668.54 million for the quarter, compared to the consensus estimate of $641.77 million. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. Axon Enterprise’s quarterly revenue was up 32.6% compared to the same quarter last year. During the same period last year, the firm posted $1.20 EPS. Axon Enterprise has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that Axon Enterprise will post 5.8 earnings per share for the current year.

Insider Buying and Selling at Axon Enterprise

In related news, Director Jeri Williams sold 100 shares of Axon Enterprise stock in a transaction dated Thursday, September 11th. The stock was sold at an average price of $752.54, for a total value of $75,254.00. Following the transaction, the director owned 1,416 shares of the company’s stock, valued at approximately $1,065,596.64. This trade represents a 6.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Jennifer H. Mak sold 77 shares of the business’s stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $760.00, for a total value of $58,520.00. Following the sale, the chief accounting officer owned 15,003 shares in the company, valued at approximately $11,402,280. The trade was a 0.51% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 49,932 shares of company stock worth $37,978,216. 5.70% of the stock is owned by insiders.

Hedge Funds Weigh In On Axon Enterprise

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Corient Private Wealth LLC grew its position in Axon Enterprise by 12.8% during the 2nd quarter. Corient Private Wealth LLC now owns 7,894 shares of the biotechnology company’s stock worth $6,536,000 after purchasing an additional 894 shares in the last quarter. Caldwell Trust Co acquired a new stake in shares of Axon Enterprise in the second quarter worth $530,000. Canal Capital Management LLC purchased a new position in shares of Axon Enterprise during the second quarter valued at $265,000. Valeo Financial Advisors LLC raised its position in Axon Enterprise by 4.0% during the second quarter. Valeo Financial Advisors LLC now owns 987 shares of the biotechnology company’s stock valued at $817,000 after buying an additional 38 shares during the period. Finally, Q3 Asset Management acquired a new position in Axon Enterprise during the second quarter valued at $728,000. Institutional investors and hedge funds own 79.08% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.